Status:
RECRUITING
Diagnostic Efficacy of EUS-FNA/B Versus ERCP With or Without POCS-TB in Patients With Suspected Hilar Cholangiocarcinoma
Lead Sponsor:
Qilu Hospital of Shandong University
Collaborating Sponsors:
First Affiliated Hospital, Sun Yat-Sen University
First Affiliated Hospital of Guangxi Medical University
Conditions:
Klatskin Tumor
Cholangiocarcinoma
Eligibility:
All Genders
18-90 years
Brief Summary
This is an observational study with a prospective cohort design. This study enrolled patients with suspected hilar cholangiocarcinoma on imaging. This study aims to evaluate the histopathological diag...
Eligibility Criteria
Inclusion
- 18-90 years old;
- Newly diagnosed patients with suspected hilar cholangiocarcinoma on imaging examination
Exclusion
- Patients with a definite diagnosis of cholangiocarcinoma by imaging (enhanced CT, MRI, or MRCP) and surgical candidacy within 3 months;
- Patients scheduled for liver transplantation;
- patients with previous gastroduodenal diversion or biliary surgery;
- Patients with hilar bile duct stenosis caused by tumor or lesion outside the bile duct;
- Pregnant or lactating women;
- Patients who cannot tolerate intravenous general anesthesia due to various reasons;
- Patients with severe coagulation dysfunction, or patients who cannot stop antiplatelet/anticoagulant therapy for a short time and are unsuitable for low molecular weight heparin replacement therapy;
- Patients who refused to sign informed consent.
Key Trial Info
Start Date :
August 14 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05993429
Start Date
August 14 2023
End Date
August 1 2027
Last Update
April 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250063